JP2015524439A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015524439A5 JP2015524439A5 JP2015525555A JP2015525555A JP2015524439A5 JP 2015524439 A5 JP2015524439 A5 JP 2015524439A5 JP 2015525555 A JP2015525555 A JP 2015525555A JP 2015525555 A JP2015525555 A JP 2015525555A JP 2015524439 A5 JP2015524439 A5 JP 2015524439A5
- Authority
- JP
- Japan
- Prior art keywords
- registered trademark
- statin
- pharmaceutical composition
- simvastatin
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 51
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 36
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 34
- 229960002855 simvastatin Drugs 0.000 claims description 34
- 238000013268 sustained release Methods 0.000 claims description 34
- 239000012730 sustained-release form Substances 0.000 claims description 34
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 33
- 239000003795 chemical substances by application Substances 0.000 claims description 33
- 229960004844 lovastatin Drugs 0.000 claims description 33
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 33
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 33
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 32
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims description 24
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 24
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 24
- 229960005370 atorvastatin Drugs 0.000 claims description 24
- 229960003765 fluvastatin Drugs 0.000 claims description 24
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 18
- 229960003512 nicotinic acid Drugs 0.000 claims description 16
- 235000001968 nicotinic acid Nutrition 0.000 claims description 16
- 239000011664 nicotinic acid Substances 0.000 claims description 16
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims description 15
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 15
- 229960002797 pitavastatin Drugs 0.000 claims description 15
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims description 15
- 229960002965 pravastatin Drugs 0.000 claims description 15
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims description 15
- 229960000672 rosuvastatin Drugs 0.000 claims description 15
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 15
- FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 claims description 12
- 229940066901 crestor Drugs 0.000 claims description 12
- 229940002661 lipitor Drugs 0.000 claims description 12
- LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 claims description 12
- PNAMDJVUJCJOIX-IUNFJCKHSA-N [(1s,3r,7s,8s,8ar)-8-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate;(3r,4s)-1-(4-fluorophenyl)-3-[(3s)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1.N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 PNAMDJVUJCJOIX-IUNFJCKHSA-N 0.000 claims description 10
- 229960000528 amlodipine Drugs 0.000 claims description 9
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 claims description 9
- 229960004034 sitagliptin Drugs 0.000 claims description 9
- 229940054572 ezetimibe / simvastatin Drugs 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 208000000044 Amnesia Diseases 0.000 claims description 4
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 4
- 208000026139 Memory disease Diseases 0.000 claims description 4
- 208000021642 Muscular disease Diseases 0.000 claims description 4
- 201000009623 Myopathy Diseases 0.000 claims description 4
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 4
- 206010039020 Rhabdomyolysis Diseases 0.000 claims description 4
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims description 4
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 4
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 4
- 229940110767 coenzyme Q10 Drugs 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 201000006370 kidney failure Diseases 0.000 claims description 4
- 230000006984 memory degeneration Effects 0.000 claims description 4
- 208000023060 memory loss Diseases 0.000 claims description 4
- 230000004065 mitochondrial dysfunction Effects 0.000 claims description 4
- 229940072168 zocor Drugs 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 7
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229940009349 vytorin Drugs 0.000 claims 2
- 239000003524 antilipemic agent Substances 0.000 description 16
- 201000001320 Atherosclerosis Diseases 0.000 description 6
- 229940022418 caduet Drugs 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- VWBQYTRBTXKKOG-IYNICTALSA-M pravastatin sodium Chemical compound [Na+].C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 VWBQYTRBTXKKOG-IYNICTALSA-M 0.000 description 6
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 4
- DEMLYXMVPJAVFU-UHFFFAOYSA-N 2-(chloromethyl)oxirane;2-methyl-1h-imidazole Chemical compound ClCC1CO1.CC1=NC=CN1 DEMLYXMVPJAVFU-UHFFFAOYSA-N 0.000 description 3
- 229920001268 Cholestyramine Polymers 0.000 description 3
- BMOVQUBVGICXQN-UHFFFAOYSA-N Clinofibrate Chemical compound C1=CC(OC(C)(CC)C(O)=O)=CC=C1C1(C=2C=CC(OC(C)(CC)C(O)=O)=CC=2)CCCCC1 BMOVQUBVGICXQN-UHFFFAOYSA-N 0.000 description 3
- JLRNKCZRCMIVKA-UHFFFAOYSA-N Simfibrate Chemical compound C=1C=C(Cl)C=CC=1OC(C)(C)C(=O)OCCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 JLRNKCZRCMIVKA-UHFFFAOYSA-N 0.000 description 3
- 229960000516 bezafibrate Drugs 0.000 description 3
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 3
- 230000001588 bifunctional effect Effects 0.000 description 3
- 229950003072 clinofibrate Drugs 0.000 description 3
- 229960001214 clofibrate Drugs 0.000 description 3
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229960002297 fenofibrate Drugs 0.000 description 3
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 3
- 229960004058 simfibrate Drugs 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical group O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 2
- 102000018616 Apolipoproteins B Human genes 0.000 description 2
- 108010027006 Apolipoproteins B Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 108010069201 VLDL Cholesterol Proteins 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000005442 diisocyanate group Chemical group 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
- 229960000815 ezetimibe Drugs 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- -1 imide ester Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261678992P | 2012-08-02 | 2012-08-02 | |
| US61/678,992 | 2012-08-02 | ||
| US201261695850P | 2012-08-31 | 2012-08-31 | |
| US201261695807P | 2012-08-31 | 2012-08-31 | |
| US61/695,850 | 2012-08-31 | ||
| US61/695,807 | 2012-08-31 | ||
| PCT/US2013/053008 WO2014022552A1 (en) | 2012-08-02 | 2013-07-31 | Methods for treatment of atherosclerosis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017194137A Division JP2018016637A (ja) | 2012-08-02 | 2017-10-04 | アテローム性硬化症の処置方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015524439A JP2015524439A (ja) | 2015-08-24 |
| JP2015524439A5 true JP2015524439A5 (enExample) | 2016-09-15 |
Family
ID=50028503
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015525555A Pending JP2015524439A (ja) | 2012-08-02 | 2013-07-31 | アテローム性硬化症の処置方法 |
| JP2015525554A Pending JP2015529655A (ja) | 2012-08-02 | 2013-07-31 | アテローム性硬化症の処置方法 |
| JP2017194137A Pending JP2018016637A (ja) | 2012-08-02 | 2017-10-04 | アテローム性硬化症の処置方法 |
| JP2017195835A Pending JP2018012726A (ja) | 2012-08-02 | 2017-10-06 | アテローム性硬化症の処置方法 |
| JP2019042213A Pending JP2019108389A (ja) | 2012-08-02 | 2019-03-08 | アテローム性硬化症の処置方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015525554A Pending JP2015529655A (ja) | 2012-08-02 | 2013-07-31 | アテローム性硬化症の処置方法 |
| JP2017194137A Pending JP2018016637A (ja) | 2012-08-02 | 2017-10-04 | アテローム性硬化症の処置方法 |
| JP2017195835A Pending JP2018012726A (ja) | 2012-08-02 | 2017-10-06 | アテローム性硬化症の処置方法 |
| JP2019042213A Pending JP2019108389A (ja) | 2012-08-02 | 2019-03-08 | アテローム性硬化症の処置方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US10201585B2 (enExample) |
| EP (6) | EP3485897A1 (enExample) |
| JP (5) | JP2015524439A (enExample) |
| CN (3) | CN104661670A (enExample) |
| AU (4) | AU2013296493B2 (enExample) |
| CA (2) | CA2880643A1 (enExample) |
| HK (2) | HK1210962A1 (enExample) |
| WO (2) | WO2014022552A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3466439A1 (en) * | 2011-12-09 | 2019-04-10 | Stealth Peptides International, Inc. | Aromatic-cationic peptides and uses of same |
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| JP2015524439A (ja) * | 2012-08-02 | 2015-08-24 | ステルス ペプチドズ インターナショナル インコーポレイテッド | アテローム性硬化症の処置方法 |
| ES3058737T3 (en) * | 2012-10-22 | 2026-03-12 | Stealth Biotherapeutics Inc | Treatment of left ventricular remodeling |
| WO2015183985A2 (en) * | 2014-05-28 | 2015-12-03 | Stealth Peptides International, Inc. | Therapeutic compositions including naphthoquinones and uses thereof |
| WO2015183970A1 (en) * | 2014-05-28 | 2015-12-03 | Stealth Peptides International, Inc. | Therapeutic compositions including flavonoid and uses thereof |
| WO2015183984A2 (en) * | 2014-05-28 | 2015-12-03 | Stealth Peptides International, Inc. | Therapeutic compositions including tocopherol and uses thereof |
| RU2623876C2 (ru) * | 2014-11-10 | 2017-06-29 | Александр Владимирович Диковский | Фармацевтическая композиция для лечения гиперлипидемии |
| WO2016190852A1 (en) * | 2015-05-26 | 2016-12-01 | Stealth Peptides International, Inc. | Therapeutic compositions including chromanyl compounds, variants and analogues thereof, and uses thereof |
| US20180318381A1 (en) * | 2015-10-23 | 2018-11-08 | University Of Pittsburgh- Of The Commonwealth System Of Higher Education | Methods of Treatment of Rhabdomyolysis |
| US11355245B2 (en) * | 2016-05-03 | 2022-06-07 | International Business Machines Corporation | Identifying and ranking risk factors using trained predictive models |
| ES2871783T3 (es) * | 2016-09-20 | 2021-11-02 | Univ Aarhus | Compuestos para el tratamiento de trastornos del metabolismo de las lipoproteínas |
| CN107041946A (zh) * | 2017-03-24 | 2017-08-15 | 南京大学 | 化合物ss‑31在制备治疗动脉粥样硬化及相关疾病药物或制剂上的应用 |
| US11034724B2 (en) | 2017-04-05 | 2021-06-15 | Stealth Biotherapeutics Corp. | Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2 |
| US10676506B2 (en) | 2018-01-26 | 2020-06-09 | Stealth Biotherapeutics Corp. | Crystalline bis- and tris-hydrochloride salt of elamipretide |
| GB202005439D0 (en) | 2020-04-14 | 2020-05-27 | Aurigen Medical Ltd | A device for occlusion of a left a trial appendage of a heart |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4489710A (en) | 1981-06-23 | 1984-12-25 | Xoma Corporation | Composition and method for transplantation therapy |
| US5156840A (en) | 1982-03-09 | 1992-10-20 | Cytogen Corporation | Amine-containing porphyrin derivatives |
| US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4625014A (en) | 1984-07-10 | 1986-11-25 | Dana-Farber Cancer Institute, Inc. | Cell-delivery agent |
| US4542225A (en) | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
| US4638045A (en) | 1985-02-19 | 1987-01-20 | Massachusetts Institute Of Technology | Non-peptide polyamino acid bioerodible polymers |
| US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| US5674534A (en) | 1992-06-11 | 1997-10-07 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5716644A (en) | 1992-06-11 | 1998-02-10 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
| US8568766B2 (en) * | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
| US7199102B2 (en) | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| ATE415412T1 (de) * | 2001-08-10 | 2008-12-15 | Novartis Pharma Gmbh | Peptide, die atherosklerotische schädigungen binden |
| ES2436011T3 (es) * | 2003-02-04 | 2013-12-26 | Cornell Research Foundation, Inc. | Métodos para prevenir la transición de la permeabilidad mitocondrial |
| CN100506841C (zh) * | 2003-05-01 | 2009-07-01 | 科内尔研究基金会 | 将分子递送到细胞的方法和载体复合物 |
| EP1718667B1 (en) | 2004-02-23 | 2013-01-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| SI1912671T1 (en) | 2005-07-18 | 2018-01-31 | Seattle Genetics, Inc. | Conjugates beta-glucuronide linker-drug |
| CA2947330C (en) * | 2005-09-16 | 2018-06-05 | Cornell Research Foundation, Inc. | Methods for reducing cd36 expression |
| EP1984026B1 (en) | 2006-01-30 | 2013-05-01 | Ben David Bryson Israel | Compositions treating cardiovascular, cerebrovascular and other vascular disease patients |
| EP2057987B1 (en) * | 2006-08-30 | 2015-03-04 | Kyushu University, National University Corporation | Pharmaceutical composition containing statin-encapsulated nanoparticle |
| WO2009092071A2 (en) * | 2008-01-18 | 2009-07-23 | Shire Llc | Amino acid and peptide pro-drugs of phenolic analgesics and uses thereof |
| CA2713150C (en) * | 2008-02-07 | 2016-01-05 | Cornell University | Methods for preventing or treating insulin resistance |
| DK2464371T3 (en) * | 2009-08-12 | 2016-06-27 | Univ Cornell | Methods for preventing or treating metabolic syndrome |
| WO2011025734A1 (en) * | 2009-08-24 | 2011-03-03 | Stealth Peptides International, Inc. | Methods and compositions for preventing or treating ophthalmic conditions |
| EP3511012A1 (en) * | 2010-02-26 | 2019-07-17 | Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") | Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy |
| EP2547352A4 (en) * | 2010-03-15 | 2013-10-09 | Stealth Peptides Int Inc | COMBINATION THERAPIES USING CYCLOSPORINE AND AROMATIC CATIONIC PEPTIDES |
| BR112013015687A2 (pt) | 2010-12-22 | 2016-10-11 | Genentech Inc | anticorpo anti-pcsk9 ou um fragmento de anticorpo que se liga a pcsk9, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar um anticorpo anti-pcsk9, composição farmacêutica, método de redução do nível de colesterol ldl em um sujeito e método de tratamento de hipercolesterolemia em um sujeito |
| JP2015524439A (ja) * | 2012-08-02 | 2015-08-24 | ステルス ペプチドズ インターナショナル インコーポレイテッド | アテローム性硬化症の処置方法 |
-
2013
- 2013-07-31 JP JP2015525555A patent/JP2015524439A/ja active Pending
- 2013-07-31 CN CN201380049785.5A patent/CN104661670A/zh active Pending
- 2013-07-31 US US14/418,809 patent/US10201585B2/en active Active
- 2013-07-31 HK HK15111866.1A patent/HK1210962A1/xx unknown
- 2013-07-31 AU AU2013296493A patent/AU2013296493B2/en active Active
- 2013-07-31 EP EP18198495.6A patent/EP3485897A1/en not_active Withdrawn
- 2013-07-31 CA CA2880643A patent/CA2880643A1/en not_active Abandoned
- 2013-07-31 CA CA2880648A patent/CA2880648A1/en not_active Abandoned
- 2013-07-31 HK HK15111769.9A patent/HK1210953A1/xx unknown
- 2013-07-31 JP JP2015525554A patent/JP2015529655A/ja active Pending
- 2013-07-31 CN CN201380049762.4A patent/CN104768564A/zh active Pending
- 2013-07-31 EP EP13825389.3A patent/EP2879689A4/en not_active Withdrawn
- 2013-07-31 US US14/418,827 patent/US10188693B2/en active Active
- 2013-07-31 EP EP13824883.6A patent/EP2879688A4/en not_active Withdrawn
- 2013-07-31 EP EP16174236.6A patent/EP3132800A1/en not_active Withdrawn
- 2013-07-31 EP EP17186931.6A patent/EP3300740A1/en not_active Withdrawn
- 2013-07-31 CN CN201910002871.XA patent/CN110090304A/zh active Pending
- 2013-07-31 WO PCT/US2013/053008 patent/WO2014022552A1/en not_active Ceased
- 2013-07-31 AU AU2013296494A patent/AU2013296494B2/en active Active
- 2013-07-31 WO PCT/US2013/053007 patent/WO2014022551A1/en not_active Ceased
- 2013-07-31 EP EP19209275.7A patent/EP3662921A1/en not_active Withdrawn
-
2017
- 2017-10-04 JP JP2017194137A patent/JP2018016637A/ja active Pending
- 2017-10-06 JP JP2017195835A patent/JP2018012726A/ja active Pending
- 2017-12-20 US US15/848,198 patent/US20180344797A1/en not_active Abandoned
- 2017-12-20 US US15/848,712 patent/US20180339012A1/en not_active Abandoned
-
2018
- 2018-03-23 AU AU2018202068A patent/AU2018202068A1/en not_active Abandoned
- 2018-03-27 AU AU2018202197A patent/AU2018202197A1/en not_active Abandoned
-
2019
- 2019-02-08 US US16/271,185 patent/US20200000870A1/en not_active Abandoned
- 2019-03-08 JP JP2019042213A patent/JP2019108389A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015529655A5 (enExample) | ||
| Jones et al. | Role of colesevelam in combination lipid-lowering therapy | |
| Kostis | The importance of managing hypertension and dyslipidemia to decrease cardiovascular disease | |
| WO2007007686A1 (ja) | 心血管イベント発症予防用組成物 | |
| Trentman et al. | Current and emerging treatments for hypercholesterolemia: A focus on statins and proprotein convertase subtilisin/kexin Type 9 inhibitors for perioperative clinicians | |
| Markel | Statins and peripheral arterial disease | |
| JP2005519052A5 (enExample) | ||
| Toth et al. | Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia | |
| ZA200102230B (en) | Method for preventing or delaying catheter-based revascularization. | |
| JP2010505866A5 (enExample) | ||
| Ho et al. | Statins and their interactions with other lipid-modifying medications: safety issues in the elderly | |
| McKenney | Combination therapy for elevated low-density lipoprotein cholesterol: the key to coronary artery disease risk reduction | |
| Rapaport et al. | Pharmacologic therapies after myocardial infarction | |
| JP6207560B2 (ja) | 膵炎を治療するためのゲムカベンおよび誘導体 | |
| Hoe et al. | Lipid management in diabetes with a focus on emerging therapies | |
| Guyton | Combination drug therapy for combined hyperlipidemia | |
| Diamantis et al. | Primary and secondary prevention of acute coronary syndromes: the role of the statins | |
| Girardi et al. | Role of bempedoic acid in patients with hypercholesterolemia and statin intolerance | |
| Roth | Diclofenac in the treatment of osteoarthritis | |
| Clearfield | Evolution of cholesterol management therapies: exploiting potential for further improvement | |
| BR102013028912A2 (pt) | composição farmacêutica, forma farmacêutica oral, cápsula, comprimido de dupla camada, usos, método de tratamento de hipercolesterolemia, hipertrigliceridemia e/ou dislipidemia mista e método de prevenção de aterosclerose, diabetes ou prevenção secundária de outras doenças cardiovasculares | |
| Brinton | Newer HMG‐CoA reductase inhibitor (statin) therapies | |
| Korth et al. | Hepatotoxic effects of lipid-altering agents | |
| AU2015202580B2 (en) | Gemcabene and derivatives for treating pancreatitis | |
| US20080146534A1 (en) | Pharmaceutical composition for reducing the risks associated with cardiovascular and cerebrovascular diseases |